Harpoon Therapeutics, Inc.
harpoontx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 9, 2023. Its latest SEC filing is a 15-12G from Mar 21, 2024.
10-Q for Q3 FY2023, filed Nov 9, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops engineered proteins that direct patients’ immune cells to attack cancer cells, for patients with solid tumors and blood cancers.
10-K for FY2022, filed Mar 27, 2023We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune…View ↗
How Did They Make Money?
Biopharmaceutical partners pay for licenses and research and development work, with additional payments tied to development, regulatory and commercial milestones and royalties on sales. Distinct license fees are earned when the partner can use the license; research-related payments come as work is carried out.
10-K for FY2022, filed Mar 27, 2023The Company enters into corporate collaborations under which it may obtain upfront license fees, research and development funding, and…View ↗
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Milestone payments: At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the…View ↗
Commercial milestones and royalties: For arrangements that include sales-based royalties, including milestone payments based on the level…View ↗
$31.9M
-
10-K for FY2022, filed Mar 27, 2023
$31.9M ↗
Who Were Their Customers?
Biopharmaceutical partners work directly with Harpoon through licensing and discovery collaborations; AbbVie is identified as a customer under both the HPN217 development agreement and the research collaborations.
10-K for FY2022, filed Mar 27, 2023We seek to selectively collaborate with leading biopharmaceutical companies to leverage our technology platforms. For example, in November…View ↗
In addition, in November 2019, we expanded our existing collaboration with AbbVie by entering into an Amended and Restated Discovery…View ↗
The Company assessed the Development and Option Agreement in accordance with Topic 606 and concluded that AbbVie is a customer under this…View ↗
The Company assessed the Original Collaboration Agreement and Restated Collaboration Agreement including the First Amendment in accordance…View ↗
Did Revenues Turn Into Profits?
No. It lost $67.7M in FY2022.
10-K for FY2022, filed Mar 27, 2023
−$68.3MView ↗
10-K for FY2022, filed Mar 27, 2023
−$67.7MView ↗
10-K for FY2022, filed Mar 27, 2023
−$89.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 9, 2023
−$1.8MView ↗
- ▼ −85% (Loss)
- vs −$11.6M in Q3 FY2022
-
Mar 11, 2024
Merck completed its acquisition of Harpoon
Common stockholders became entitled to $23.00 in cash per share, and Harpoon requested Nasdaq delisting.
Sources
8-K, filed Mar 11, 2024
Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (a) each share of Harpoon Common Stock (other…View ↗
-
Jan 8, 2024
Agreed to be acquired by Merck for $23.00 per common share
Sources
8-K, filed Jan 8, 2024
At the effective time of the Merger (the “Effective Time”), (a) each share of common stock, par value $0.0001 per share, of the Company…View ↗
-
Nov 9, 2023
Ended AbbVie’s HPN217 license-option agreement
Harpoon retained the program and planned to complete the ongoing Phase 1 trial.
Sources
8-K, filed Nov 9, 2023
In September, Harpoon announced the termination of the Development and Option Agreement, which granted AbbVie an option to a worldwide…View ↗
Grew. Revenue grew 6.7x in 4 years, from $4.8M in FY2018 to $31.9M in FY2022, about 61% a year.
Broader drug-candidate platform
The earlier report described its candidate pipeline as using TriTAC; the latest report identifies a candidate from the ProTriTAC platform and says additional candidates are moving toward IND-enabling studies.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Mar 27, 2023We are leveraging our proprietary TriTAC and ProTriTAC platforms to discover and develop product candidates to treat cancer and other…View ↗
Two programs discontinued or paused
The earlier report described clinical programs for prostate and mesothelin-expressing tumors; the latest report says the prostate-targeting program was discontinued and enrollment in the mesothelin program stopped while it sought a partner.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Mar 27, 2023In March 2022, we announced the discontinuation of our clinical development program for HPN424, our Prostate-Specific Membrane Antigen…View ↗
Who Did They Compete With?
Competes with AbbVie, Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer, Roche/Genentech, Boehringer Ingelheim, Allogene Therapeutics, Janssen Pharmaceuticals, Regeneron Pharmaceuticals, Autolus Therapeutics, Arcellx, bluebird bio, Legend Biotech, GlaxoSmithKline, and Celgene/Sutro Pharmaceuticals
10-K for FY2022, filed Mar 27, 2023We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immuno-oncology treatments. There…View ↗
Loading...
